Nihr‑funded phase 2 study to assess progesterone delivery using Callavid device

Findings support once‑daily dosing and reinforce PALI‑2108’s potential

Study expands evaluation of survivin‑targeting vaccine

UK spin‑out speeds up development and reduces animal testing

Boehringer Ingelheim reports significant reductions in weight

Partnership to support selection of first neoantigen therapy candidate

Collaboration aims to create integrated platform from discovery to IND submission

Lead asset shows systemic, dose‑dependent anti‑tumour activity

US study marks company’s second clinical trial of ovarian cancer therapy

Clesrovimab is first monoclonal antibody offering a single fixed dose for infants